Document is current

Article History

Received: 20 July 2024

Revised: 6 October 2024

Accepted: 11 November 2024

First Online: 8 January 2025

Compliance with ethical standards

:

: The scientific guarantor of this publication is Philip Konietzke.

: P.K. has no relevant relationships. O.W. airway analysis technology is licensed to Imbio, LLC. S.M.F.T. has no relevant relationships. S.N. has no relevant relationships. F.W. has no relevant relationships. M.K. employee at Boehringer Ingelheim. B.J.J. has no relevant relationships. C.F.V. grants or contracts from the German Ministry of Education and Science (BMBF), AstraZeneca, Boehringer Ingelheim, Grifols, GlaxoSmithKline, and Novartis; consulting fees from Aerogen, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, and Nuvaira; payment or honoraria for lectures/presentations from Aerogen, AstraZeneca, Boehringer Ingelheim. R.A.J. has no relevant relationships. H.-U.K. Bayer provided consumables to the consortium; the institution receives payment from Siemens, Philips, and Boehringer Ingelheim; consulting fees to the author from Median; and payment or honoraria for lectures/presentations to the author from Siemens, Philips, Boehringer Ingelheim, MSD, and Sanofi. C.P.H. grants/contracts from Siemens (2012–2014), Pfizer (2012–2014), MeVis (2012, 2013), Boehringer Ingelheim (2014), and German Center for Lung Research (2011ff); consulting fees from Schering-Plough (2009 and 2010), Pfizer (2008–2014), Basilea (2008, 2009, and 2010), Boehringer Ingelheim (2010–2014), Novartis (2010, 2012, and 2014), Roche (2010), Astellas (2011 and 2012), Gilead (2011–2015), MSD (2011–2013), Lilly (2011), Intermune (2013–2014), and Fresenius (2013 and 2014); lecture fees from Gilead (2008–2014), Essex (2008, 2009, and 2010), Schering-Plough (2008, 2009, and 2010), AstraZeneca (2008–2014 and 2022), Lilly (2008, 2009, and 2012), Roche (2008 and 2009), MSD (2009–2014), Pfizer (2010–2014), Bracco (2010 and 2011), MEDA Pharma (2011), Intermune (2011–2014), Chiesi (2012), Siemens (2012), Covidien (2012), Pierre Fabre (2012), Boehringer Ingelheim (2012, 2013, and 2022), Grifols (2012), Novartis (2013–2016), Basilea (2015 and 2016), and Bayer (2016); patent: Method and Device For Representing the Microstructure of the Lungs. IPC8 Class: AA61B5055FI, PAN: 20080208038, Inventors: W Schreiber, U Wolf, AW Scholz, C.P.H.; participation on a data safety monitoring board or advisory board: Schering-Plough (2009 and 2010), Pfizer (2008–2014), Basilea (2008, 2009, and 2010), Boehringer Ingelheim (2010–2014, 2022ff), Novartis (2010, 2012, and 2014), Roche (2010), Astellas (2011 and 2012), Gilead (2011–2015), MSD (2011–2013), Lilly (2011), Intermune (2013–2014), Fresenius (2013 and 2014); leadership or fiduciary roles: chest working group of the German Roentgen Society (national guidelines: bronchial carcinoma, mesothelioma, COPD, screening for bronchial carcinoma, CT and MRI of the chest, pneumonia); consultant of ECIL-3, ECCMID, EORTC/MSG (guideline for diagnosis of infections in immunocompromised hosts); founding member of the working team in infections in immunocompromised hosts of the German Society of Hematology/Oncology (guideline for diagnosis of infections in immunocompromised hosts); faculty member of European Society of Thoracic Radiology (ESTI), European Respiratory Society (ERS), and member in EIBALL (European Imaging Biomarkers Alliance); editor of Medizinische Klinik, Intensivmedizin und Notfallmedizin at Springer publishing; stock/stock options GSK. B.J.J. has no relevant relationships. M.O.W. Bayer provided contrast material for MRI examinations; study grants were paid to institutions from Vertex Pharmaceuticals and Boehringer Ingelheim; and consultancy fees were paid to institutions from Vertex Pharmaceuticals and Boehringer Ingelheim. J.B. Siemens Healthineers helped with MRI protocol design; Bayer provided contrast material used in the study; payment for honorarium for presentation at a workshop from Roche, Boehringer Ingelheim, and Fuji; and president of the European Society of Thoracic Imaging 2022–2023.

: No complex statistical methods were necessary for this paper.

: Written informed consent was obtained from all subjects (patients) in this study.

: Institutional ethics committee approval was obtained (Ethik-Kommission der Medizinischen Fakultät der Universität Heidelberg, S-656/2012) and all subjects gave their written informed consent prior to the study conduct.

: Some study subjects or cohorts have been previously reported in (Phenotyping of COPD with MRI in comparison to same-day CT in a multi-center trial) and “COPD phenotyping based on QCT” (under review).

: